Head-To-Head Review: Halozyme Therapeutics (HALO) vs. Its Rivals

Halozyme Therapeutics (NASDAQ:HALO) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Halozyme Therapeutics to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent ratings for Halozyme Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1	5	7	0	2.46
Halozyme Therapeutics Competitors	9903	15310	45655	1602	2.54

Halozyme Therapeutics presently has a consensus price target of $108.18, indicating a potential upside of 7.89%. As a group, “Biotechnology” companies have a potential upside of 127.05%. Given Halozyme Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Halozyme Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	26.93%	751.81%	23.84%
Halozyme Therapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Institutional & Insider Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Halozyme Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ rivals have a beta of -1.90, indicating that their average stock price is 290% less volatile than the S&P 500.

Valuation & Earnings

This table compares Halozyme Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Halozyme Therapeutics	$1.40 billion	$316.89 million	25.51
Halozyme Therapeutics Competitors	$713.66 million	$10.27 million	-18.80

Halozyme Therapeutics has higher revenue and earnings than its rivals. Halozyme Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Halozyme Therapeutics beats its rivals on 8 of the 13 factors compared.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.